|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Metoprolol succinate#Warnings]] |
| {{metoprolol}}
| |
| {{CMG}}
| |
| | |
| {| style="border: 3px solid #696969;"
| |
| | style="background: #000000; border: 0px; padding: 20px 20px; width: 800px;" |
| |
| <center>
| |
| <font color="#F8F8FF">'''WARNING: ISCHEMIC HEART DISEASE'''</font>
| |
| </center>
| |
| | |
| <center>
| |
| <font color="#F8F8FF" size="1">''See full prescribing information for complete boxed warning.''</font>
| |
| </center>
| |
| | |
| | |
| <b><font color="#F8F8FF">
| |
| Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered TOPROL-XL, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1 - 2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, TOPROL-XL administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Warn patients against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue TOPROL-XL therapy abruptly even in patients treated only for hypertension.
| |
| </font></b>
| |
| |}
| |